Celldex Therapeutics, Inc. (CLDX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Celldex Therapeutics, Inc. (CLDX)
Go deeper and ask any question about CLDX
Company Performance
Current Price
as of Sep 13, 2024$44.16
P/E Ratio
N/A
Market Cap
$2.93B
Description
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Metrics
Overview
- HQHampton, NJ
- SectorHealth Technology
- IndustryBiotechnology
- TickerCLDX
- Price$44.16+5.77%
Trading Information
- Market Cap$2.93B
- Float96.86%
- Average Daily Volume (1m)613,935
- Average Daily Volume (3m)707,538
- EPS-$2.74
Company
- Revenue$8.30M
- Rev Growth (1yr)832.09%
- Net Income-$35.84M
- Gross Margin68.09%
- EBITDA Margin-1,822.26%
- EBITDA-$45.52M
- EV$1.65B
- EV/Revenue198.53
- P/EN/A
- P/S351.17
Documents
SEC Filings
Factset Street Account